Last reviewed · How we verify
LVGN6051 Monoclonal Antibody Injection
LVGN6051 Monoclonal Antibody Injection is a PD-1 inhibitor Biologic drug developed by Lyvgen Biopharma Holdings Limited. It is currently in Phase 2 development for Metastatic non-small cell lung cancer, PD-L1 positive. Also known as: LVGN6051.
LVGN6051 targets the PD-1 receptor to inhibit cancer cell growth and immune evasion.
LVGN6051 targets the PD-1 receptor to inhibit cancer cell growth and immune evasion. Used for Metastatic non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | LVGN6051 Monoclonal Antibody Injection |
|---|---|
| Also known as | LVGN6051 |
| Sponsor | Lyvgen Biopharma Holdings Limited |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to the PD-1 receptor, LVGN6051 prevents cancer cells from evading the immune system, allowing the immune system to attack and destroy cancer cells. This mechanism is similar to other PD-1 inhibitors, which have shown efficacy in various types of cancer.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LVGN6051 Monoclonal Antibody Injection CI brief — competitive landscape report
- LVGN6051 Monoclonal Antibody Injection updates RSS · CI watch RSS
- Lyvgen Biopharma Holdings Limited portfolio CI
Frequently asked questions about LVGN6051 Monoclonal Antibody Injection
What is LVGN6051 Monoclonal Antibody Injection?
How does LVGN6051 Monoclonal Antibody Injection work?
What is LVGN6051 Monoclonal Antibody Injection used for?
Who makes LVGN6051 Monoclonal Antibody Injection?
Is LVGN6051 Monoclonal Antibody Injection also known as anything else?
What drug class is LVGN6051 Monoclonal Antibody Injection in?
What development phase is LVGN6051 Monoclonal Antibody Injection in?
What are the side effects of LVGN6051 Monoclonal Antibody Injection?
What does LVGN6051 Monoclonal Antibody Injection target?
Related
- Drug class: All PD-1 inhibitor drugs
- Target: All drugs targeting PD-1
- Manufacturer: Lyvgen Biopharma Holdings Limited — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic non-small cell lung cancer, PD-L1 positive
- Also known as: LVGN6051
- Compare: LVGN6051 Monoclonal Antibody Injection vs similar drugs
- Pricing: LVGN6051 Monoclonal Antibody Injection cost, discount & access